As proof-of-principle, the team designs a potent anti-cancer compound.
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
“This is the first time therapeutic small molecules have been rationally designed from only an RNA sequence—something many doubted could be done,” said Matthew Disney, PhD, an associate professor at TSRI who led the study. “In this case, we have shown that that approach allows for specific and unprecedented targeting of an RNA that causes cancer.”
The technique, described in the journal Nature Chemical Biology online ahead of print on February 9, 2014, was dubbed Inforna.
“With our program, we can identify compounds with high specificity,” said Sai Pradeep Velagapudi, the first author of the study and a graduate student working in the Disney lab. “In the future, we hope we can design drug candidates for other cancers or for any pathological RNA.”
In Search of New Approaches
In their research program, Disney and his team has been developing approaches to understand the binding of drugs to RNA folds. In particular, the lab is interested in manipulating microRNAs.
Discovered only in the 1990s, microRNAs are short molecules that work within virtually all animal and plant cells. Typically each one functions as a “dimmer switch” for one or more genes; it binds to the transcripts of those genes and effectively keeps them from being translated into proteins. In this way microRNAs can regulate a wide variety of cellular processes.
Some microRNAs have been associated with diseases. MiR-96 microRNA, for example, is thought to promote cancer by discouraging a process called apoptosis or programmed cell death that can rid the body of cells that begin to grow out of control.
As part of its long-term program, the Disney lab developed computational approaches that can mine information against such genome sequences and all cellular RNAs with the goal of identifying drugs that target such disease-associated RNAs while leaving others unaffected.
“In recent years we’ve seen an explosion of information about the many roles of RNA in biology and medicine,” said Peter Preusch, PhD, of the National Institute of Health‘s National Institute of General Medical Sciences, which partially funded the research. “This new work is another example of how Dr. Disney is pioneering the use of small molecules to manipulate disease-causing RNAs, which have been underexplored as potential drug targets.”
In the new study, Disney and colleagues describe their computational technique, which identifies optimal drug targets by mining a database of drug-RNA sequence (“motif”) interactions against thousands of cellular RNA sequences.
Using Inforna, the team identified compounds that can target microRNA-96, as well as additional compounds that target nearly two dozen other disease-associated microRNAs.
The researchers showed that the drug candidate that inhibited microRNA-96 inhibited cancer cell growth. Importantly, they also showed that cells without functioning microRNA-96 were unaffected by the drug.
“This illustrates an unparalleled selectivity for the compound,” Disney noted. “In contrast, typical cancer therapeutics target cells indiscriminately, often leading to side effects that can make these drugs difficult for patients to tolerate.”
Disney added that the new drug candidate, which is easy to produce and cell permeable, targets microRNA-96 far more specifically than the state-of-the-art method to target RNA (using oligonucleotides) currently in use. “That’s unprecedented and provides great excitement for future developments.”
The Latest on: New medicines
via Google News
The Latest on: New medicines
- Can this Israeli corovavirus drug 'completely prevent' lung damage?on May 13, 2020 at 11:35 am
Bonus BioGroup has completed a preliminary study of a new drug to treat acute and life-threatening respiratory distress in COVID-19 patients.
- Coronavirus research updates: New York City’s infection hotspots have high numbers of commuterson May 13, 2020 at 11:15 am
New York City’s infection hotspots have high numbers of commuters. New York City neighbourhoods that were COVID-19 hotspots between March and May correlate with those ...
- Suspect in drug-related triple killing faces new murder chargeon May 13, 2020 at 9:32 am
Joshua Kelsey, 35, faces another murder charge related to the May 6 crime spree that left three men dead and a fourth wounded.
- Minnesota has a new drug price transparency law. Here's what it doeson May 13, 2020 at 8:23 am
Drug companies will have to notify Minnesota consumers about big prescription medication price hikes, under a major compromise measure signed into law on Tuesday. The new price transparency law, which ...
- Mimicking nature's best medicine opens door to new treatmentson May 13, 2020 at 6:33 am
Discoveries made by a University of Canterbury (UC) organic chemist could be a springboard to new treatments for cancers and antibiotic resistant infections.
- Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesitieson May 13, 2020 at 6:27 am
FDA grants Priority Review of application and sets PDUFA goal date of November 27, 2020 –BOSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Rhythm ...
- The new COVID-19 drug remdesivir is here. Now what?on May 13, 2020 at 3:04 am
Though remdesivir, a new treatment for COVID-19, has been hailed as a game changer, most people sick with the coronavirus will have to recover or die without getting the drug. “Everyone won’t be able ...
- Local teacher shows promising recovery from coronavirus after receiving new drugon May 12, 2020 at 3:20 pm
A local elementary school teacher received a promising update as she battles complications from the novel coronavirus.
- Maine CDC reports 15 new COVID-19 cases, as hospitals get anti-viral drugon May 12, 2020 at 2:40 pm
No new deaths were reported Tuesday and the state received a shipment of remdesivir, a new drug that has shown promise treating COVID-19 in hospitalized patients.
- New drug, contact tracing part of Minnesota's next COVID-19 phaseon May 12, 2020 at 10:29 am
The Minnesota Department of Health is on track by week's end to employ 460 contact investigators to identify cases early and try to keep small COVID-19 clusters from exploding among entire businesses ...
via Bing News